“Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo”. 2023. SKIN The Journal of Cutaneous Medicine 7 (6): s272. https://doi.org/10.25251/skin.7.supp.272.